Published in Gene Therapy Weekly, December 8th, 2011
"Nevertheless, in vivo delivery of siRNA remains a crucial challenge for its therapeutic success. siRNAs on their own are not taken-up by most mammalian cells in a way that preserves their activity," wrote W. Fischer and colleagues, University of Tel Aviv.
The researchers concluded: "Moreover, when applied in vivo, siRNA-based approaches are all limited by poor penetration into the target...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.